Evidence map›Paper›PMID 31989476›Full record

ReviewArchives of pharmacal research2020

Single enzyme nanoparticle, an effective tool for enzyme replacement therapy.

Dong Hyun Kim, Han Sol Lee, Tae-Wan Kwon, Young-Min Han, Nae-Won Kang, Mee Yeon Lee, Dae-Duk Kim, Myeong Gyu Kim, Jae-Young Lee

Abstract readReview
PubMed Publisher
In one paragraph

Review in Archives of pharmacal research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dong Hyun KimCollege of Pharmacy, Chungnam National University, Daejeon, 34134, Republic of Korea.
Han Sol LeeCollege of Pharmacy, Chungnam National University, Daejeon, 34134, Republic of Korea.
Tae-Wan KwonCollege of Pharmacy, Chungnam National University, Daejeon, 34134, Republic of Korea.
Young-Min HanCollege of Pharmacy, Chungnam National University, Daejeon, 34134, Republic of Korea.
Nae-Won KangCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, Republic of Korea.
Mee Yeon LeeDepartment of Pharmacy, Seoul National University Seoul Metropolitan Government Boramae Medical Center, Seoul, 07610, Republic of Korea.
Dae-Duk KimCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, Republic of Korea.
Myeong Gyu KimGraduate School of Clinical Pharmacy, CHA University, Pocheon, 11160, Republic of Korea. kimmg@cha.ac.kr.
Jae-Young LeeCollege of Pharmacy, Chungnam National University, Daejeon, 34134, Republic of Korea. jaeyoung@cnu.ac.kr.ORCID http://orcid.org/0000-0002-8093-043X

Funding

Ministry of Science and ICT (KR) NRF-2018M3A7B4071204Ministry of Science and ICT (KR) NRF-2018R1C1B6005379
6 · The paper itself

Abstract

The term "single enzyme nanoparticle" (SEN) refers to a chemically or biologically engineered single enzyme molecule. SENs are distinguished from conventional protein nanoparticles in that they can maintain their individual structure and enzymatic activity following modification. Furthermore, SENs exhibit enhanced properties as biopharmaceuticals, such as reduced antigenicity, and increased stability and targetability, which are attributed to the introduction of specific moieties, such as poly(ethylene glycol), carbohydrates, and antibodies. Enzyme replacement therapy (ERT) is a crucial therapeutic option for controlling enzyme-deficiency-related disorders. However, the unfavorable properties of enzymes, including immunogenicity, lack of targetability, and instability, can undermine the clinical significance of ERT. As shown in the cases of Adagen®, Revcovi®, Palynziq®, and Strensiq®, SEN can be an effective technology for overcoming these obstacles. Based on these four licensed products, we expect that additional SENs will be introduced for ERT in the near future. In this article, we review the concepts and features of SENs, as well as their preparation methods. Additionally, we summarize different types of enzyme deficiency disorders and the corresponding therapeutic enzymes. Finally, we focus on the current status of SENs in ERT by reviewing FDA-approved products.

Indexed as

Enzyme Replacement TherapyAdenosine DeaminaseAlkaline PhosphataseHumansImmunoglobulin GNanoparticlesPhenylalanine Ammonia-LyaseRecombinant Fusion ProteinsRecombinant ProteinsAdenosine DeaminaseAlkaline Phosphataseasfotase alfaelapegademaseImmunoglobulin GpegvaliasePhenylalanine Ammonia-LyaseRecombinant Fusion ProteinsRecombinant ProteinsBiologicsEnzyme deficiencyEnzyme replacement therapyEnzyme therapeuticsSingle enzyme nanoparticle

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.